title: The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients.
abstract: BACKGROUND
  Discontinuation of antipsychotic drugs in schizophrenia patients is a major concern, since it results in relapse and re-hospitalizations. Non-adherence is strongly associated with negative-subjective response to antipsychotics, which is composed of the subjective experience of negative drug effects and attitude towards the treatment.
  
  
  OBJECTIVE
  To investigate the elements of subjective experience and subjective attitude towards specific drug-related adverse effects, leading to a generally negative-subjective attitude towards antipsychotics.
  
  
  METHODS
  Schizophrenia inpatients (n=84) were administered a questionnaire measuring attitude and experience on eight subscales: weight gain, sedation, sexual anhedonia, extra-pyramidal syndrome, affective flattening, excessive sleep, diminished sociability and metabolic syndrome. DAI-30 was used to measure attitude towards drugs, and PANSS to assess psychopathology.
  
  
  RESULTS
  Weak correlation was found between subjective experience and attitude on most of the subscales. The only strong, albeit inverse, correlation between experience and attitude that was found was with regard to affective flattening, experienced by 37% of the sample, and it also predicted negative drug attitude as measured by the DAI-30, RR: 1.87 (95% CI: 1.06-3.3, df=1, χ(2)=4.525, P<0.05).
  
  
  CONCLUSIONS
  Negative attitude towards most adverse drug effects did not correlate with personal experience. Drug-related affective flattening should be evaluated routinely, since experiencing it may predict negative attitude towards drugs, potentially leading to poor compliance and relapse.
authors.affiliation: Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100 Petach-Tikva, Israel; Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: T
authors.initials: T
authors.lastname: Fischel
authors.forename: A
authors.initials: A
authors.lastname: Krivoy
authors.forename: M
authors.initials: M
authors.lastname: Kotlarov
authors.forename: Z
authors.initials: Z
authors.lastname: Zemishlany
authors.forename: O
authors.initials: O
authors.lastname: Loebstein
authors.forename: H
authors.initials: H
authors.lastname: Jacoby
authors.forename: A
authors.initials: A
authors.lastname: Weizman
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001290:Attitude; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents